A Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial With Open‐Label Extension of Sirona, a Hydrogel for Weight Loss
Obesity · 2026
DOI: 10.1002/oby.70066 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Obesity, 2026. Verfasst von James P Byrne und 9 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, UK. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Hydrogels, Obesity, Weight Loss. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovate UK Biomedical Catalyst Grant, Oxford Medical Products Ltd., Innovate UK.
Abstract (Originalsprache)
Objective
This study investigated the safety, tolerability, and preliminary efficacy of Sirona, a novel gastro‐retentive, dual‐network polymer for weight management.
Methods
This pilot trial comprised a randomized, parallel‐group, double‐blind, placebo‐controlled (3:1 ratio), 12‐week period, with a 12‐week open‐label extension (OLE), in participants with BMI of 30–40 kg/m 2 . Primary endpoints were feasibility, tolerability, and safety; secondary endpoints included weight loss and dietary intake, tested using Hedge's g [95% CI] as a measure of effect size.
Results
Participants received Sirona ( n = 29/38) or Placebo ( n = 9/38) (mean [SD] age = 40.9 [8.4]; weight = 101.7 [12.9] kg; BMI = 35.6 [3.0]; 29/38 female and 23/38 White British). Dosing was well tolerated (RCT Sirona: 95.2 [11.0]%; RCT Placebo: 97.8 [3.5]%; RCT + OLE Sirona: 93.1 [13.0]%). No serious adverse events occurred. Of the adverse events, nausea was most prominent (74.8%), mostly graded mild (79.3%) and requiring no intervention (84.4%). Percentage total body weight loss was greater for Sirona compared to Placebo after 12 weeks (3.9 [3.0]% versus 1.0 [2.1]%, g = 0.96 [−1.81, −0.10]). Weight loss continued in the OLE (change from baseline = 4.4 [3.8]%). Dietary intake reduced from baseline after 12 weeks of treatment (−382.5 [519.3] kcal; Placebo = 93.5 [670.3] kcal, g = −0.8 [−1.7, 0.0]) and after 24 weeks (−338.2 [486.7] kcal, g = 0.7 [0.2, 1.1]).
Conclusions
Sirona was well tolerated, with mild, primarily gastrointestinal side effects. Reduced weight and dietary intake suggest Sirona is suitable as a nonpharmacological treatment for weight management. Trial Registration ISRCTN14083641 ( https://doi.org/10.1186/ISRCTN14083641 )
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NIHR Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, UK.
- NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston Trust and University of Bristol, Bristol, UK.
- Oxford Medical Products Limited, Witney, UK.
- Milton Keynes University Hospital Foundation Trust, Milton Keynes, UK.
- Department of Bariatric and Metabolic Surgery, North Bristol NHS Trust, Southmead Hospital, Bristol, UK.
ORCID-Profile: Elanor C Hinton
Förderung
- Innovate UK Biomedical Catalyst Grant
- Oxford Medical Products Ltd.
- Innovate UK
Zitieren
APA
Byrne, J. P., Hinton, E. C., Humayun, A. M., Pournaras, D. J., Elsworth, R. L., Brunstrom, J. M., Hamilton-Shield, J. P., Sumeray, M., Easter, C., & Ashrafian, H. (2026). A Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial With Open‐Label Extension of Sirona, a Hydrogel for Weight Loss. Obesity. https://doi.org/10.1002/oby.70066
Vancouver
Byrne JP, Hinton EC, Humayun AM, Pournaras DJ, Elsworth RL, Brunstrom JM, et al. A Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial With Open‐Label Extension of Sirona, a Hydrogel for Weight Loss. Obesity. 2026. doi:10.1002/oby.70066
BibTeX
@article{Byrne2026,
author = {Byrne, James P and Hinton, Elanor C and Humayun, Asif Malik and Pournaras, Dimitri J and Elsworth, Rebecca L and Brunstrom, Jeffrey M and Hamilton-Shield, Julian P and Sumeray, Mark and Easter, Camilla and Ashrafian, Hutan},
title = {A Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial With Open‐Label Extension of Sirona, a Hydrogel for Weight Loss},
journal = {Obesity},
year = {2026},
doi = {10.1002/oby.70066}
}
EUVIMED